NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
LESCOL XL (fluvastatin sodium) by Novartis is hmg-coa reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) to mevalonate, a precursor of cholesterol. First approved in 2000.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LESCOL XL is an extended-release oral tablet containing fluvastatin sodium, a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis. It is indicated for patients with elevated cholesterol levels who require lipid-lowering therapy. The drug works by blocking a key enzyme in the cholesterol biosynthesis pathway, reducing LDL cholesterol and cardiovascular risk.
$0.722MPart D
LOE ApproachingDeclining
Declining revenue trajectory with minimal Part D claims indicates a mature, commoditized product facing significant generic erosion; brand teams are likely small and focused on managed decline rather than expansion.
Mechanism of Action
HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Started Jan 2012
436 enrolled
Lipid Metabolism Disorders
Career Relevance
LESCOL XL offers limited career growth opportunity due to its LOE-approaching status and minimal linked job availability. Professionals joining this product would focus on managed decline, generic mitigation, and cost control rather than market expansion or innovation—suitable for consolidation or transition roles but not for career acceleration.
Brand Manager
Worked on LESCOL XL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.